Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in Active Pharmaceutical Ingredients (APIs) in selected high-growth therapeutic areas and a major focus on anti-retroviral, Hepatitis C, and oncology drugs
with SL at 330 , one can go for target mentioned in chart
Market Cap
₹ 20,407 Cr.
Stock P/E
25.8
Book Value
₹ 70.5
Dividend Yield
0.53 %
ROCE
23.4 %
ROE
24.6 %
Face Value
₹ 2.00
Promoter holding
27.3 %
EPS last year
₹ 14.0
EPS latest quarter
₹ 4.23
Debt
₹ 1,925 Cr.
Pledged percentage
0.04 %
Net CF
₹ 1.55 Cr.
Price to Cash Flow
24.8
Free Cash Flow
₹ 61.6 Cr.
Debt to equity
0.51
Volume
1,195,742
OPM last year
27.3 %
OPM 5Year
25.0 %
Reserves
₹ 3,679 Cr.
Price to book value
5.38
Int Coverage
10.3
PEG Ratio
0.85
with SL at 330 , one can go for target mentioned in chart
Market Cap
₹ 20,407 Cr.
Stock P/E
25.8
Book Value
₹ 70.5
Dividend Yield
0.53 %
ROCE
23.4 %
ROE
24.6 %
Face Value
₹ 2.00
Promoter holding
27.3 %
EPS last year
₹ 14.0
EPS latest quarter
₹ 4.23
Debt
₹ 1,925 Cr.
Pledged percentage
0.04 %
Net CF
₹ 1.55 Cr.
Price to Cash Flow
24.8
Free Cash Flow
₹ 61.6 Cr.
Debt to equity
0.51
Volume
1,195,742
OPM last year
27.3 %
OPM 5Year
25.0 %
Reserves
₹ 3,679 Cr.
Price to book value
5.38
Int Coverage
10.3
PEG Ratio
0.85